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ABSTRACT
Objective Antitumour necrosis factor (anti- TNF) drugs 
impair protective immunity following pneumococcal, 
influenza and viral hepatitis vaccination and increase 
the risk of serious respiratory infections. We sought to 
determine whether infliximab- treated patients with IBD 
have attenuated serological responses to SARS- CoV-2 
infections.
Design Antibody responses in participants treated 
with infliximab were compared with a reference cohort 
treated with vedolizumab, a gut- selective anti- integrin 
α4β7 monoclonal antibody that is not associated with 
impaired vaccine responses or increased susceptibility to 
systemic infections. 6935 patients were recruited from 92 
UK hospitals between 22 September and 23 December 
2020.
Results Rates of symptomatic and proven SARS- 
CoV-2 infection were similar between groups. 
Seroprevalence was lower in infliximab- treated than 
vedolizumab- treated patients (3.4% (161/4685) vs 
6.0% (134/2250), p<0.0001). Multivariable logistic 
regression analyses confirmed that infliximab (vs 
vedolizumab; OR 0.66 (95% CI 0.51 to 0.87), p=0.0027) 
and immunomodulator use (OR 0.70 (95% CI 0.53 to 
0.92), p=0.012) were independently associated with 
lower seropositivity. In patients with confirmed SARS- 
CoV-2 infection, seroconversion was observed in fewer 
infliximab- treated than vedolizumab- treated patients 
(48% (39/81) vs 83% (30/36), p=0.00044) and the 
magnitude of anti- SARS- CoV-2 reactivity was lower 
(median 0.8 cut- off index (0.2–5.6) vs 37.0 (15.2–76.1), 
p<0.0001).
Conclusions Infliximab is associated with attenuated 
serological responses to SARS- CoV-2 that were further 
blunted by immunomodulators used as concomitant 
therapy. Impaired serological responses to SARS- CoV-2 
infection might have important implications for global 
public health policy and individual anti- TNF- treated 
patients. Serological testing and virus surveillance should 
be considered to detect suboptimal vaccine responses, 
persistent infection and viral evolution to inform public 
health policy.
Trial registration number ISRCTN45176516.
Significance of this study
What is already known on this subject?
 ► Antitumour necrosis factor (anti- TNF) drugs 
are effective treatments for immune- mediated 
inflammatory diseases (IMIDs); however, by 
suppressing immune responses, they impair 
vaccine effectiveness and increase susceptibility to 
serious infection.
 ► In the early phase of the COVID-19 pandemic, 
patients with IMIDs treated with anti- TNF drugs 
were subject to the most restrictive public health 
measures.
 ► Registry studies have not reported an increased risk 
of adverse outcomes from SARS- CoV-2 in patients 
treated with anti- TNF therapies. However, the 
impact of these therapies on serological responses 
and subsequent immunity to SARS- CoV-2 infection 
remains unknown.
What are the new findings?
 ► Rates of symptomatic and proven SARS- CoV-2 
infection were similar between infliximab- treated 
and vedolizumab- treated patients with IBD.
 ► Seroprevalence, seroconversion and the magnitude 
of anti- SARS- CoV-2 antibody reactivity was 
significantly attenuated in infliximab- treated 
patients compared with vedolizumab- treated 
patients.
 ► Concomitant immunomodulator use with a 
thiopurine or methotrexate further blunted 
serological responses to SARS- CoV-2 infection 
in infliximab- treated patients, with only a third 
of patients having detectable anti- SARS- CoV-2 
antibodies.
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INTRODUCTION
Induction of protective immunity following SARS- CoV-2 infec-
tion and/or vaccination is critical to suppress transmission. By 
suppressing immune responses, biological and immunosuppres-
sion therapies may lead to chronic SARS- CoV-2 infection and 
have recently been implicated in the evolution and emergence of 
novel variants.1–3
Immune- mediated inflammatory diseases (IMIDs) including 
IBD, the inflammatory arthritides and psoriasis affect about 
3%–7% of Western populations.4 5 Drugs targeting tumour 
necrosis factor (TNF) are the most frequently prescribed biolog-
ical therapies used in the treatment of IMIDs with over 2 million 
patients receiving treatment worldwide.6 However, anti- TNF 
drugs impair protective immunity following pneumococcal,7 
influenza8 and viral hepatitis9 vaccinations and increase the risk 
of serious infection, most notably with respiratory pathogens.10 
Consequently, in the early phase of the COVID-19 pandemic, 
patients with IMIDs treated with anti- TNF drugs were advised 
to follow strict social distancing measures, and some, depending 
on the severity of their condition, were advised to shield.11 Data 
from disease- specific registries are reassuring, however, citing 
similar rates and risk factors for SARS- CoV-2 infection, hospital-
isation and outcomes to background populations.12–14 Whether 
anti- TNF drugs impair serological responses and subsequent 
immunity to SARS- CoV-2 infection is unknown.
We hypothesised that anti- SARS- CoV-2 antibody responses 
would be impaired following SARS- CoV-2 infection in patients 
with IBD treated with infliximab, a commonly prescribed 
anti- TNF drug. To test this hypothesis, we compared antibody 
responses in patients with IBD treated with infliximab with a 
reference cohort treated with vedolizumab. Vedolizumab is a 
gut- selective anti- integrin α4β7 monoclonal antibody, adminis-
tered in hospital with the same dosing schedule as infliximab 
and is not associated with increased susceptibility to systemic 
infection or attenuated serological responses to vaccination.15
Objectives
We aimed to define, in patients with IBD, whether biological 
class, concomitant use of an immunomodulator and/or social 
distancing measures impact:
1. Seroprevalence of SARS- CoV-2.
2. Subsequent seroconversion in patients with infection confirmed 
by prior PCR testing.
3. Magnitude of anti- SARS- CoV-2 reactivity.
METHODS
Patient and settings
ImpaCt of bioLogic therApy on saRs- cov-2 Infection and immu-
niTY (CLARITY) IBD is a UK wide, multicentre, prospective 
observational cohort study investigating the impact of infliximab 
and vedolizumab and/or concomitant immunomodulators (thio-
purines or methotrexate) on SARS- CoV-2 acquisition, illness 
and immunity in patients with IBD.
Consecutive patients were recruited at the time of attendance 
at infusion units from 92 National Health Service (NHS) hospi-
tals across the UK (see online supplemental table S1) between 22 
September 2020 and 23 December 2020.
The eligibility criteria were:
1. Age 5 years and over.
2. Diagnosis of IBD.
3. Current treatment with infliximab or vedolizumab for 6 
weeks or more, with at least one dose of drug received in the 
past 16 weeks.
Patients were excluded if they had participated in a 
SARS- CoV-2 vaccine trial.
Here we report the seroprevalence of anti- SARS- CoV-2 anti-
bodies at entry to the CLARITY IBD study.
Outcome measures
The primary outcome was the proportion of participants with a posi-
tive anti- SARS- CoV-2 antibody test. Secondary outcomes were the 
proportion of participants with a positive anti- SARS- CoV-2 antibody 
following a positive PCR test to SARS- CoV-2 and the magnitude of 
the anti- SARS- CoV-2 antibody reactivity.
Variables
Variables recorded by participants included demographics (age, sex, 
ethnicity, comorbidities, height and weight, smoking status and post-
code), IBD disease activity (PRO2),16 17 IBD- related quality of life 
(IBD control),18 mental well- being (Patient Health Questionnaire 
depression scale19 and General Anxiety Disorder Assessment),20 
SARS- CoV-2 outcomes aligned to the COVID-19 symptoms study21 
(symptoms, previous testing and hospital admissions for COVID-
19) and social distancing behaviour during the lockdown periods. 
During lockdown, the population of the UK was instructed to adhere 
to restrictions on social and professional activities with specific 
advice to vulnerable groups to undertake more extreme social exclu-
sion measures referred to as shielding.11
Study sites completed data relating to IBD history (age at diag-
nosis, disease duration and phenotype according to the Montreal 
classifications,22 previous surgeries and duration of current biological 
and immunomodulator therapy).
Wherever possible, data were entered electronically into a 
purpose- designed REDCap database hosted at the Royal Devon and 
Exeter NHS Foundation Trust.23 At sites without access to electronic 
devices or the internet, participants completed their questionnaires 
on paper case record forms that were subsequently entered by local 
research teams.
Case definition
Cases were defined according to the recently published WHO 
framework.24 In brief, this framework uses symptoms and 
the results of nucleic acid amplification testing to determine 
whether patients are suspected, probable or confirmed cases 
of COVID-19. Participants who reported fever and cough, 
or anosmia/ageusia or any three or more of the following 
symptoms: fever, cough, general weakness/fatigue, myalgia, 
sore throat, coryza, dyspnoea, and altered mental status were 
Significance of this study
How might it impact on clinical practice in the foreseeable 
future?
 ► For the individual anti- TNF- treated patient, lower rates of 
seroconversion and reduced anti- SARS- CoV-2 antibody reactivity 
levels may increase their susceptibility to recurrent COVID-19.
 ► Impaired serological responses might lead to chronic 
nasopharyngeal colonisation that may act as a reservoir to drive 
persistent transmission and the evolution of new SARS- CoV-2 
variants.
 ► Serological testing and virus surveillance should be considered to 
detect suboptimal vaccine responses, persistent infection and viral 
evolution to inform public health policy.
 ► If attenuated serological responses following vaccination are also 
observed, then modified immunisation strategies will need to be 
designed for millions of patients worldwide.
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considered suspected/probable COVID-19 cases. We omitted 
the GI symptoms because patients with active IBD may suffer 
anorexia, nausea, vomiting and diarrhoea. We linked our data 
by NHS number or Community Health Index to Public Health 
England, Scotland and Wales who archive dates and results of 
all SARS- CoV-2 PCR tests undertaken in the UK. Confirmed 
cases were those participants with a positive PCR test to SARS 
CoV-2.
Table 1 Baseline characteristics stratified by biological therapy
Variable Infliximab Vedolizumab Overall P value
Age (years) 37.1 (27.2–50.6) 43.8 (31.9–58.6) 39.0 (28.7–53.2) <0.0001
Sex
  Female 45.5 (2134/4685) 48.3 (1087/2250) 46.4 (3221/6935) 0.089
  Male 54.3 (2546/4685) 51.5 (1159/2250) 53.4 (3705/6935)
  Intersex 0.0 (1/4685) 0.0 (1/2250) 0.0 (2/6935)
  Prefer not to say 0.1 (4/4685) 0.1 (3/2250) 0.1 (7/6935)
Ethnicity
  White 88.5 (4143/4683) 88.2 (1981/2247) 88.4 (6124/6930) 0.20
  Asian 6.6 (308/4683) 7.6 (171/2247) 6.9 (479/6930)
  Mixed 2.2 (104/4683) 2.3 (51/2247) 2.2 (155/6930)
  Black 1.8 (82/4683) 1.2 (27/2247) 1.6 (109/6930)
  Other 1.0 (46/4683) 0.8 (17/2247) 0.9 (63/6930)
Diagnosis
  Crohn’s disease 66.6 (3121/4685) 36.8 (828/2250) 56.9 (3949/6935) 0.00050
  UC 31.1 (1457/4685) 60.1 (1353/2250) 40.5 (2810/6935)
  IBD unclassified 2.3 (107/4685) 3.1 (69/2250) 2.5 (176/6935)
Duration of IBD (years) 7.0 (3.0–15.0) 9.0 (4.0–16.0) 8.0 (3.0–15.0) <0.0001
Age at IBD diagnosis (years) 26.3 (18.9–37.5) 30.4 (21.6–44.1) 27.6 (19.8–39.8) <0.0001
Immunomodulators at recruitment 56.3 (2639/4685) 18.8 (424/2250) 44.2 (3063/6935) <0.0001
5- ASA at recruitment 22.2 (1039/4685) 35.2 (791/2250) 26.4 (1830/6935) <0.0001
Steroid use in 2020 14.2 (664/4685) 21.9 (492/2250) 16.7 (1156/6935) <0.0001
BMI 24.4 (21.5–28.1) 24.9 (22.0–28.4) 24.5 (21.7–28.2) 0.044
Heart disease 2.1 (97/4685) 5.0 (113/2250) 3.0 (210/6935) <0.0001
Diabetes 3.4 (158/4685) 6.8 (154/2250) 4.5 (312/6935) <0.0001
Lung disease 12.6 (588/4685) 16.7 (375/2250) 13.9 (963/6935) <0.0001
Kidney disease 0.9 (42/4685) 2.1(47/2250) 1.3 (89/6935) <0.0001
Cancer 0.2 (11/4685) 1.7 (39/2250) 0.7 (50/6935) <0.0001
Smoker
  Yes 11.5 (538/4684) 9.2 (206/2249) 10.7 (744/6933) 0.00050
  Not currently 28.5 (1333/4684) 34.4 (773/2249) 30.4 (2106/6933)
  Never 60.1 (2813/4684) 56.5 (1270/2249) 58.9 (4083/6933)
Meets clinical criteria for suspected or probable COVID-19 8.3 (389/4685) 8.9 (201/2250) 8.5 (590/6935) 0.38
Tested with PCR for SARS- CoV-2 36.5 (1712/4685) 39.0 (877/2250) 37.3 (2589/6935) 0.050
Positive PCR for SARS- CoV-2 5.2 (89/1712) 4.3 (38/877) 4.9 (127/2589) 0.39
Positive PCR for SARS- CoV-2 at least 2 weeks prior to serum sample 5.3 (81/1537) 4.4 (36/809) 5.0 (117/2346) 0.43
Hospitalised for confirmed COVID-19 0.2 (8/4685) 0.2 (5/2250) 0.2 (13/6935) 0.77
Shielding behaviour April–July
  I remained in my house or garden 35.2 (1647/4681) 33.3 (749/2248) 34.6 (2396/6929) 0.41
  I only left the house for exercise on my own or with members of my household 38.5 (1804/4681) 39.9 (897/2248) 39.0 (2701/6929)
  I encountered people from outside of my household but maintained social 
distancing
24.4 (1142/4681) 24.6 (554/2248) 24.5 (1696/6929)
  I encountered people from outside of my household but did not maintain 
social distancing
1.9 (88/4681) 2.1 (48/2248) 2.0 (136/6929)
Exposure to documented cases of COVID-19 11.4 (533/4683) 10.7 (240/2250) 11.1 (773/6933) 0.39
PHQ8 4.0 (1.0–8.0) 5.0 (1.0–9.0) 4.0 (1.0–9.0) 0.018
GAD-7 3.0 (0.0–7.0) 3.0 (0.0–7.0) 3.0 (0.0–7.0) 0.12
Income deprivation score 0.099 (0.057–0.168) 0.095 (0.056–0.160) 0.097 (0.57–0.165) 0.24
Active disease (PRO2) 6.7 (303/4534) 12.6 (272/2166) 8.6 (575/6700) <0.0001
IBD Control 8 13.0 (10.0–16.0) 13.0 (9.0–16.0) 13.0 (9.0–16.0) 0.024
IBD Control VAS 80.0 (66.0–93.0) 79.0 (61.0–91.0) 80.0 (65.0–92.0) 0.00022
Values shown are medians (IQR) and percentages (proportions) as appropriate.
5- ASA, 5- aminosalicylate; BMI, body mass index; GAD-7, General Anxiety Disorder Assessment; PHQ8, Patient Health Questionnaire depression scale; PRO2, Patient Reported 
Outcome; VAS, visual analogue scale.
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Laboratory methods
Laboratory analyses were performed at the Academic Depart-
ment of Blood Sciences at the Royal Devon and Exeter NHS 
Foundation Trust. We used the Roche Elecsys Anti- SARS- CoV-2 
immunoassay to detect antibodies to SARS- CoV-2 in serum 
samples.25 This sandwich electrochemiluminescence immuno-
assay uses a recombinant protein of the nucleocapsid antigen 
for the determination of antibodies against SARS- CoV-2. The 
electrochemiluminescence signal from a negative and positive 
calibrator is assigned a value of 0.8 and 1.2, respectively, and 
a cut- off is set at a signal equivalent to 1. The electrochem-
iluminescence signal from the reaction product of the sample 
is compared with the cut- off signal and expressed as positive 
when ≥1.0 or negative when <1, as well as quantitatively in 
the form of a cut- off index (COI; calculated by sample signal/
cut- off signal).
In house assay validation experiments demonstrated the 
intra- assay and interassay coefficient of variation were 2.2% 
and 7.0%, respectively. No effect was observed on recovery of 
anti- SARS- CoV-2 antibodies following four freeze/thaw cycles. 
SARS- CoV-2 antibodies were stable in uncentrifuged blood 
and serum at ambient temperature for up to 7 days permitting 
postal transport from research sites to the central laboratory. No 
analytical interference was observed for the detection of anti- 
SARS- CoV-2 with infliximab or vedolizumab up to 10 000 mg/L 
and 60 000 mg/L, respectively, or with antidrug antibodies to 
infliximab or vedolizumab up to 400 AU/mL and 38 AU/mL, 
respectively.
Study size
Limited data are available regarding the risk of SARS- CoV-2 in 
patients with IBD to inform sample size calculations.
Table 2 Seroprevalence to anti- SARS- CoV-2, stratified by baseline 
characteristics
Variable Seroprevalence P value
Biological therapy
  Infliximab 3.4 (161/4685) <0.0001
  Vedolizumab 6.0 (134/2250)
Biological/immunomodulator therapy
  Infliximab with immunomodulator 3.0 (78/2639) 0.00050
  Infliximab without immunomodulator 4.1 (83/2046)
  Vedolizumab with immunomodulator 4.5 (19/424)




  Female 4.3 (137/3221) 1.0
  Male 4.3 (158/3705)
  Intersex 0.0 (0/2)
  Prefer not to say 0.0 (0/7)
Ethnicity
  White 3.5 (217/6124) 0.00050
  Asian 9.2 (44/479)
  Mixed 7.7 (12/155)
  Black 13.8 (15/109)
  Other 11.1 (7/63)
Diagnosis
  Crohn’s disease 3.2 (128/3949) 0.00050
  UC 5.5 (155/2810)
  IBD unclassified 6.8 (12/176)
Immunomodulators at recruitment
  No 5.1 (198/3872) <0.0001
  Yes 3.2 (97/3063)
5- ASA at recruitment
  No 3.9 (198/5105) 0.012
  Yes 5.3 (97/1830)
Steroid use in 2020
  No 4.0 (232/5779) 0.031
  Yes 5.4 (63/1156)
Heart disease
  No 4.3 (287/6725) 0.86
  Yes 3.8 (8/210)
Diabetes
  No 4.2 (280/6623) 0.57
  Yes 4.8 (15/312)
Lung disease
  No 4.4 (260/5972) 0.34
  Yes 3.6 (35/963)
Kidney disease
  No 4.3 (294/6846) 0.19
  Yes 1.1 (1/89)
Cancer
  No 4.3 (293/6885) 1.0
  Yes 4.0 (2/50)
Smoker
  Yes 2.2 (16/744) 0.00050
  Not currently 3.4 (71/2106)
  Never 5.1 (207/4083)
Meets clinical criteria for suspected or probable COVID-19
  No 2.5 (158/6345) <0.0001
  Yes 23.2 (137/590)
Tested with PCR for SARS- CoV-2
  No 2.9 (128/4346) <0.0001
  Yes 6.5 (167/2589)
Continued
Variable Seroprevalence P value
Positive PCR for SARS- CoV-2
  No 3.8 (93/2462) <0.0001
  Yes 58.3 (74/127)
Positive PCR for SARS- CoV-2 at least 2 weeks prior to serum sample
  No 3.8 (85/2229) <0.0001
  Yes 59.0 (69/117)
Hospitalised for confirmed COVID-19
  No 4.1 (285/6922) <0.0001
  Yes 76.9 (10/13)
Shielding behaviour April–July
  I remained in my house or garden 3.8 (92/2396) 0.0020
  I only left the house for exercise 
on my own or with members of my 
household
3.9 (104/2701)
  I encountered people from outside of 
my household but maintained social 
distancing
4.9 (83/1696)
  I encountered people from outside of 
my household but did not maintain 
social distancing
11.0 (15/136)
Exposure to documented cases of COVID-19
  No 3.1 (192/6160) <0.0001
  Yes 13.3 (103/773)
Active disease (PRO2)
  No 4.3 (266/6125) 0.67
  Yes 3.8 (22/575)
Values shown are percentages (proportions).
5- ASA, aminosalicylates; PRO2, patient- reported outcome.
Table 2 Continued
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The following assumptions were made to determine our 
sample size:
 ► Proportion of patients treated with each drug(s): vedol-
izumab: 30% (20% with concomitant immunomodulator), 
infliximab: 70% (60% with concomitant immunomodulator).
 ► Seroprevalence of SARS- CoV-2 in the background popula-
tion: 0.05.
 ► OR for SARS- CoV-2 seropositivity with immunomodulator 
use: 0.8.
 ► OR SARS- CoV-2 seropositivity for infliximab versus 
vedolizumab:≤0.7.
 ► Attrition rate: 20%.
We calculated that a sample size of 6970 patients would provide 
80% power for the comparison of infliximab versus vedolizumab, 
controlling for immunosuppressant status in a multivariable logistic 
regression model at the 0.05 significance level.
Ethical consideration and roles of funders
CLARITY IBD is an investigator- led, UK National Institute for 
Health Research COVID-19 urgent public health study funded 
by the Royal Devon and Exeter NHS Foundation Trust, Hull 
University Teaching Hospital NHS Trust and by unrestricted 
educational grants from F. Hoffmann- La Roche AG (Switzer-
land), Biogen GmbH(Switzerland), Celltrion Healthcare (South 
Korea) and Galapagos NV (Belgium).
None of our funding bodies had any role in study design, data 
collection or analysis, writing or decision to submit for publica-
tion. Patients were included after providing informed, written 
consent. The sponsor was the Royal Devon and Exeter NHS 
Foundation Trust. The protocol is available online at https//
www. clarityibd. org. The study was registered with the ISRCTN 
registry.
Statistics
Statistical analyses were undertaken in R V.4.0.3 (R Foun-
dation for Statistical Computing, Vienna, Austria). All tests 
were two tailed, and p values<0.05 were considered signifi-
cant. We included participants in the primary analysis if they 
had completed the patient questionnaire and had an anti- 
SARS- CoV-2 serology result at visit 1. We included patients 
with missing clinical data in analyses for which they had data 
and have specified the denominator for each variable. Contin-
uous data were reported as median and IQR, and discrete data 
as numbers and percentages, unless otherwise stated. We used 
patients’ postcodes to assign them to one of the ten UK adminis-
trative regions and present seroprevalence rates mapped to these 
regions. We also used postcodes to derive participants’ income 
and employment deprivation scores using combined English 
and Welsh data from 201926 and Scottish data from 2020.27 
Univariable analyses, using Fisher’s exact and Mann- Whitney U 
tests were used to identify demographic, disease and treatment 
related factors associated with SARS- CoV-2 seropositivity. A 
priori, we included age, sex, ethnicity, region, income depriva-
tion score, comorbidity, body mass index and social distancing 
measures that are known to affect SARS- CoV-2 acquisition and 
COVID-19 outcomes28 alongside IBD diagnosis, biological ther-
apies, immunomodulator and 5- aminosalicylate use. We used 
multivariable logistic regression models to identify factors inde-
pendently associated with seropositivity.
We undertook Fisher’s exact and Mann- Whitney U tests to 
compare the rates of, and time to, seroconversion in infliximab- 
treated and vedolizumab- treated patients with confirmed 
COVID-19 and to identify factors associated with failure of 
seroconversion in infliximab- treated patients. We explored the 
magnitude of antibody reactivity using density plots, stratified by 
drug exposure among participants with a positive PCR to anti- 
SARS- CoV-2 at least 2 weeks prior to measurement of serology.
We conducted sensitivity analyses using propensity matching 
to account for significant differences in baseline variables 
between infliximab- treated and vedolizumab- treated patients 
using the MatchIt package.29 Patients were matched exactly on 
diagnosis, immunomodulator use and cancer and then using 




Between 22 September 2020 and 23 December 2020, 7226 
patients were recruited from 92 UK hospitals. Serum samples and 
completed questionnaires were available in 96.0% (6935/7226) 
patients. Of these, 67.6% (4685/6935) were treated with inflix-
imab and 32.4% (2250/6935) were treated with vedolizumab. 
Participant characteristics are shown in table 1.
Adherence to social distancing measures during the UK 
lockdown period between April and July 2020 and expo-
sure to COVID-19 cases were similar between infliximab and 
vedolizumab treated patients (table 1). Fewer infliximab- 
treated patients were tested by PCR for SARS- CoV-2 (36.5% 
(1712/4685) vs 39.0% (877/2250), p=0.050). There were 
no differences between the proportions of infliximab- treated 
and vedolizumab- treated patients who: reported symptoms of 
suspected or probable COVID-19 (8.3% (389/4685) vs 8.9% 
(201/2250), p=0.38); tested positive by PCR for SARS- CoV-2 
(5.2% (89/1712) vs 4.3% (38/877), p=0.39); or were hospi-
talised with confirmed COVID-19 (0.2% (8/4685) vs 0.2% 
(5/2250), p=0.77).
Seroprevalence of anti-SARS-CoV-2 antibodies in anti-TNF 
and vedolizumab-treated patients
Overall, the seroprevalence of anti- SARS- CoV-2 antibodies was 
4.3% (295/6935, 95% CI 3.8% to 4.8%). The proportion of 
patients with a positive anti- SARS- CoV-2 antibody test was 
lower in infliximab- treated than vedolizumab- treated patients 
(3.4% (161/4685) vs 6.0% (134/2250), p<0.0001) (table 2).
Seropositivity was also associated with younger age, non- white 
ethnicity, UK region, higher income deprivation score, having 
never smoked, UC, no concomitant immunomodulator use, 
recent steroid use, exposure to confirmed cases of COVID-19, 
reported symptoms of suspected or probable COVID-19, and 
social distancing measures during the UK government’s lock-
down period (tables 2 and 3, See online supplemental figure S1).
Multivariable logistic regression analyses confirmed that 
infliximab (vs vedolizumab; OR 0.66 (95% CI 0.51 to 0.87), 
p=0.0027) and immunomodulator use (OR 0.70 (95% CI 0.53 
to 0.92), p=0.012) were independently associated with lower 
seropositivity (figure 1). Conversely, non- white ethnicity, several 
UK regions, higher income deprivation score and non- adherence 
to social distancing measures were independently associated 
with an increased risk of SARS- CoV-2 seropositivity. There was 
no significant interaction between the effect of infliximab (vs 
vedolizumab) and immunomodulator use (OR for interaction 
term 1.03 (95% CI 0.57 to 1.92), p=0.92). In our propen-
sity matched analysis, we confirmed lower seroprevalence in 
infliximab- treated compared with vedolizumab- treated patients 
3.9% (67/1704) versus 6.2% (105/1707) p=0.0037 (online 
supplemental table S2).
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Seroconversion in patients with confirmed SARS-CoV-2 
infection
Sensitivity analyses in participants with confirmed SARS- CoV-2 
infection demonstrated that fewer infliximab- treated than 
vedolizumab- treated patients had seroconverted (48% (39/81) vs 
83% (30/36), p=0.00044). The magnitude of anti- SARS- CoV-2 
reactivity was lower in patients with previous PCR- confirmed 
SARS- CoV-2 infection treated with infliximab than with 
vedolizumab (median 0.8 COI (0.2–5.6) vs 37.0 (15.2–76.1), 
p<0.0001; figure 2). This difference was also seen restricting 
our analyses to participants whose antibody reactivity results 
were above the threshold (1 COI) for seropositivity (p<0.0001; 
see online supplemental figure S2).
Failure of seroconversion was associated with concomitant immu-
nomodulator use. In patients treated with infliximab alone, the 
seroconversion rate was 60% (24/40) and in patients treated with 
infliximab and immunomodulator combination therapy, the rate was 
37% (15/41, p=0.046). There was also a significant difference in 
the magnitude of anti- SARS- CoV-2 reactivity (p=0.035; see online 
supplemental figure S3). The median interval from a positive PCR 
test to serological testing at recruitment in infliximab- treated patients 
was 32 days (IQR 20–54) and for vedolizumab- treated patients was 
40 days (IQR 24–83) (p=0.082). An increase in anti- SARS- CoV-2 
antibody reactivity was observed 4 weeks after a positive PCR test 
in vedolizumab- treated patients (47.2 COI (IQR 24.1–113.0) vs 
14.5 COI (IQR 0.4–30.7), p=0.0079) but not infliximab- treated 
patients (0.7 COI (IQR 0.2–7.5) vs 1.1 COI (IQR 0.4–4.5), p=0.70) 
(figure 3).
DISCUSSION
We have shown that infliximab- treated patients have attenuated 
serological responses to SARS- CoV-2 infection with lower sero-
prevalence, seroconversion and antibody reactivity. Similar rates 
of symptomatic and proven SARS- CoV-2 infection and hospi-
talisations between infliximab- treated and vedolizumab- treated 
patients suggest that our findings cannot be explained by differ-
ences in acquisition or severity of infection alone. Rather, inflix-
imab seems to be directly influencing the serological response 
to infection. Concomitant immunomodulator use with a thio-
purine or methotrexate further blunted serological responses 
to both drugs with fewer than half of patients (37%) having 
Figure 1 Forest plot showing the coefficients from a multivariable logistic regression model of associations with a positive anti- SARS- CoV-2 
antibody. abbreviations: 5- ASA, 5- aminosalicylates; IBDU, IBD unclassified.
Table 3 Baseline characteristics, stratified by baseline anti- SARS- 
CoV-2 antibody status
Variable Positive Negative P value
Age (years) 36.3 (26.9–50.6) 39.2 (28.7–53.3) 0.017
Duration of IBD (years) 7.0 (3.0–15.0) 8.0 (3.0–15.0) 0.25
Age at IBD diagnosis 
(years)
26.4 (19.8–36.4) 27.6 (19.8–40.0) 0.12
BMI 24.7 (21.7–28.1) 24.5 (21.7–28.3) 0.75
PHQ8 4.0 (1.0–8.0) 4.0 (1.0–9.0) 0.40
GAD-7 2.0 (0.0–6.0) 3.0 (0.0–7.0) 0.050
Income deprivation score 0.120 (0.666–0.204) 0.097 (0.056–0.163) <0.0001
IBD Control 8 13.0 (10.0–16.0) 13.0 (9.0–16.0) 0.32
IBD Control VAS 79.0 (67.0–92.0) 80.0 (65.0–92.0) 0.61
Values shown are medians (IQR).
BMI, body mass index; GAD-7, General Anxiety Disorder Assessment; PHQ8, Patient Health 
Questionnaire depression scale; VAS, visual analogue scale.
Figure 2 Density plot of the magnitude of anti- SARS- CoV-2 antibody 
reactivity stratified by biological therapy among participants who had a 
positive PCR to anti- SARS- CoV-2 at least 2 weeks prior to their serology 
sample. COI, cut- off index.
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detectable anti- SARS- CoV-2 antibodies after a median of 5.4 
weeks following PCR confirmed infection.
Infliximab may directly impede the immune mechanisms respon-
sible for generating antibody responses. This is biologically plausible, 
since the proinflammatory actions of TNF include stimulation of B 
cell immunoglobulin synthesis, induction of germinal centre forma-
tion, costimulation of antigen- activated T cells and maturation of 
antigen presenting cells.30–32
Impaired serological responses to SARS- CoV-2 infection might 
have important implications for global public health policy and indi-
vidual anti- TNF treated patients. From a public health perspective, 
impaired serological responses might lead to chronic nasopharyngeal 
colonisation that may act as a reservoir to drive persistent transmis-
sion and the evolution of new SARS- CoV-2 variants.2 Virus surveil-
lance will define if persistent infection and viral evolution occurs in 
this patient group.3
For the individual anti- TNF treated patient, lower rates of 
seroconversion and reduced anti- SARS- CoV-2 antibody reac-
tivity levels may ultimately increase their susceptibility to recur-
rent COVID-19.
Accepting that vaccination is critical to suppress transmission, 
serology testing should be considered to detect suboptimal vaccine 
responses to inform the need for the most restrictive social distancing 
measures to protect patients and public health. If attenuated sero-
logical responses following vaccination are observed, then modified 
vaccination schedules given in combination might need to be consid-
ered in these patients.
Any negative impact on seroconversion following infection or 
vaccination needs to be balanced against theoretical benefits for the 
individual patient of reducing the excessive cytokine production that 
characterises severe COVID-19 disease. Indeed, this is the ratio-
nale behind the proposals for trials of anti- TNF therapy in severe 
COVID-19 (ISRCTN40580903 and ISRCTN33260034).33
Our study has other important findings. We have identi-
fied associations of SARS- CoV-2 seropositivity with non- white 
ancestry and non- adherence to social distancing guidance. These 
findings are consistent with observations reported in general non- 
immunosuppressed populations.28 The mechanisms underlying 
these associations are complex and multifactorial and likely include 
multigenerational living, at- risk employment, inability to work from 
home, socioeconomic deprivation and religious congregation.
The region- specific seroprevalence rates for vedolizumab- 
treated patients are consistent with those reported in the general 
UK population. While direct comparisons with other datasets 
are limited, confounded in part by differences in the time of 
testing during the pandemic and the diagnostic accuracies of 
the anti- SARS- CoV-2 assays used, this adds to the evidence that 
patients with IBD are at a similar risk of SARS- CoV-2 infection 
as the general population.34
The main strength of this study was our recruitment of over 
7000 consecutive patients within a narrow window mitigating 
against the potential for time during the pandemic course to 
be a significant covariate. Other strengths include comprehen-
sive electronic collection of patient- reported outcomes, linkage 
with SARS- CoV-2 public health testing data, case ascertainment 
aligned with the WHO criteria, inclusion of social distancing 
behaviours and the use of a sensitive and specific serological 
assay.35
Limitations
We acknowledge, however, the following limitations. First, it is 
not known whether attenuated immune responses in infliximab- 
treated patients translates into increased risk of infection. More-
over, we only assessed humoral responses to infection, and it is 
likely that protective immunity additionally requires induction of 
memory T cell responses. Second, our patient- reported data are 
subject to recall bias that may have underestimated the prevalence 
of possible COVID-19 symptoms. Third, the only anti- TNF drug 
investigated in this study was infliximab. However, we suspect 
that our key findings apply to other anti- TNF monoclonal anti-
bodies used to treat IMIDs, including adalimumab, certolizumab 
and golimumab.
CONCLUSIONS
In summary, infliximab therapy is associated with attenuated 
serological responses to SARS- CoV-2 infection. Poor antibody 
responses in infliximab- treated patients were observed despite 
similar rates of symptomatic and proven SARS- CoV-2 infec-
tion as vedolizumab- treated patients. Anti- SARS- CoV-2 anti-
body responses were further attenuated in infliximab recipients 
concomitantly treated with immunomodulators, including thio-
purines and methotrexate.
Impaired serological responses to SARS- CoV-2 infection might 
have important implications for global public health policy and 
millions of anti- TNF treated patients. Serological testing and 
virus surveillance should be considered to detect suboptimal 
vaccine responses, persistent infection and viral evolution to 
inform public health policy.
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